Stay updated on Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the confirmed response rate (RR) in a non-irradiated site based on the best responding abscopal lesion in a single-arm phase 2 study involving pembrolizumab and concurrent radiation for patients with previously treated carcinoma of unknown primary.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:16.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria 6' section has been updated to provide a detailed explanation of eligibility criteria, including examples such as general health condition or prior treatments. Additionally, it now includes specific inclusion criteria like written informed consent and HIPAA authorization prior to registration.
    Difference
    63%
    Check dated 2024-05-22T21:29:46.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:24:56.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Radiation in Cancer of Unknown Primary Clinical Trial page.